75 related articles for article (PubMed ID: 8911576)
21. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
22. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
[TBL] [Abstract][Full Text] [Related]
24. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
25. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
26. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
[TBL] [Abstract][Full Text] [Related]
27. Antiribonucleoprotein antibodies in children with human immunodeficiency virus infection: comparative study with childhood-onset systemic lupus erythematosus.
González CM; López-Longo FJ; Monteagudo I; Grau R; Rodríguez-Mahou M; St-Cyr C; Lapointe N; Carreño L
Pediatr AIDS HIV Infect; 1996 Dec; 7(6):401-8. PubMed ID: 11361496
[TBL] [Abstract][Full Text] [Related]
28. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen.
Greidinger EL; Zang Y; Jaimes K; Hogenmiller S; Nassiri M; Bejarano P; Barber GN; Hoffman RW
Arthritis Rheum; 2006 Feb; 54(2):661-9. PubMed ID: 16453294
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases.
Combe B; Rucheton M; Graafland H; Lussiez V; Brunel C; Sany J
Clin Exp Immunol; 1989 Jan; 75(1):18-24. PubMed ID: 2702772
[TBL] [Abstract][Full Text] [Related]
30. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
31. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
32. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
34. T-cell epitopes on the 70-kDa protein of the (U1)RNP complex in autoimmune rheumatologic disorders.
O'Brien RM; Cram DS; Coppel RL; Harrison LC
J Autoimmun; 1990 Dec; 3(6):747-57. PubMed ID: 1708263
[TBL] [Abstract][Full Text] [Related]
35. Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease.
Scherl M; Posch U; Obermoser G; Ammann C; Sepp N; Ulmer H; Dierich MP; Stoiber H; Falkensammer B
Lupus; 2006; 15(12):865-72. PubMed ID: 17211992
[TBL] [Abstract][Full Text] [Related]
36. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up.
Piirainen HI
Br J Rheumatol; 1990 Oct; 29(5):345-8. PubMed ID: 2224402
[TBL] [Abstract][Full Text] [Related]
37. Antibodies to small ribonucleoprotein and to 73-kD heat shock protein: two distinct markers of mixed connective tissue disease.
Appelboom T; Kahn MF; Mairesse N
Clin Exp Immunol; 1995 Jun; 100(3):486-8. PubMed ID: 7774060
[TBL] [Abstract][Full Text] [Related]
38. U1-RNP and TLR receptors in the pathogenesis of mixed connective tissue diseasePart I. The U1-RNP complex and its biological significance in the pathogenesis of mixed connective tissue disease.
Paradowska-Gorycka A
Reumatologia; 2015; 53(2):94-100. PubMed ID: 27407234
[TBL] [Abstract][Full Text] [Related]
39. The speckled epidermal nuclear immunofluorescence of mixed connective tissue disease seems to develop as an in vitro phenomenon.
Iwatsuki K; Tagami H; Imaizumi S; Ginoza M; Yamada M
Br J Dermatol; 1982 Dec; 107(6):653-7. PubMed ID: 6756463
[TBL] [Abstract][Full Text] [Related]
40. Identification of retroviral conserved pol sequences in serum of mixed connective tissue disease and systemic sclerosis patients.
Prokop J; Jagodzinski PP
Biomed Pharmacother; 2004 Jan; 58(1):61-4. PubMed ID: 14739063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
